Search clinical trials for: Neutral Protamine Hagedorn (NPH) insulin

Total 597 results

The University of Texas Health Science Center,...

Completed

Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy (Determin)

Diabetes Mellitus, Type 2

United States
University of Texas Southwestern Medical Center
Novo Nordisk A/S

Terminated

Duration of The Honeymoon Phase of Type 1 Diabetes: A Comparison of Insulins Detemir, Glargine and NPH

Type 1 Diabetes

United States
Sanofi

Completed

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes (PRESCHOOL)

Type 1 Diabetes Mellitus

United States, Austria, Brazil, Chile, Czech Republic, Germany, Hungary, India, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Turkey
Assiut University

Completed

Insulin in Treatment of Diabetes Mellitus With Pregnancy

Diabetes
Eli Lilly and Company
Alkermes, Inc.

Completed

A Study for Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Vancouver General Hospital

Terminated

Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (PTHG)

Post-Transplant Glucocorticoid Induced Diabetes

Canada
Elaine Chow
Sanofi

Completed

Toujeo Versus NPH Self-titration Study

Diabetes Mellitus, Type 2

Hong Kong
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE) (IOPE)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Brazil, Canada
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY) (IOOY)

Diabetes Mellitus Type 2

Korea, Republic of, Hungary, United States, Mexico, Argentina, India, Poland, Taiwan, Spain
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Geropharm

Completed

Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Pharmacokinetics | Bioequivalence

Russian Federation
Fudan University
Novo Nordisk A/S

Unknown

Study on Liver Fat Content and Visceral Fat Mass in Overweight and Obese Type 2 Diabetes Patients After Treatment With Basal Insulin

Type 2 Diabetes Mellitus

China
Eli Lilly and Company

Completed

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes (IOOZ)

Diabetes Mellitus, Type 1

Russian Federation, United States, Australia, Greece, Argentina, Hungary, Brazil, Mexico, Romania
Dennis G. Karounos, M.D.
Novo Nordisk A/S

Completed

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy (VIISTA)

Type 2 Diabetes Mellitus

United States
Tehran University of Medical Sciences

Completed

Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients

Diabetes Type 2

Iran, Islamic Republic of
Munich Municipal Hospital
Novo Nordisk A/S

Unknown

Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes

Type 2 Diabetes Mellitus

Germany
Emory University
Sanofi

Completed

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis

United States
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes | Type 2 Diabetes Mellitus

Taiwan, Turkey, India, Algeria, Hong Kong, China, Ukraine
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Inmunova S.A.
Linical Co., Ltd.; KLIXAR; PHV LATAM

Completed

A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

Hemolytic-Uremic Syndrome | Pediatric Kidney Disease | Diarrhea-Associated Hemolytic Uremic Syndrome

Argentina
Providence Health & Services

Withdrawn

Comparison Study of Insulin Glargine and NPH Insulin

Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

Diabetes Mellitus, Type 2 | Diabetes

Denmark
Hennepin Healthcare Research Institute
Eli Lilly and Company

Completed

Inpatient Diabetes on Corticosteroids

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes (SimpleMix™)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom, Poland, Spain, India, Argentina, China
Novo Nordisk A/S

Completed

Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes (Start)

Diabetes Mellitus, Type 2 | Diabetes

Sweden
Novo Nordisk A/S

Completed

Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Poland
Novo Nordisk A/S

Completed

Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes (ProMix)

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Post Marketing Surveillance Study of Biphasic Insulin Aspart 30

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

Mexico
Biologics & Biosimilars Collective Intelligence...
Merck Sharp & Dohme LLC; Pfizer; AbbVie; University of Pittsburgh; Boehringer Ingelheim and other collaborators

Completed

Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics

Diabetes
Novo Nordisk A/S

Completed

Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers

Healthy | Diabetes

United States
Eli Lilly and Company

Completed

Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Eli Lilly and Company

Completed

A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Romania, Italy, Belgium, Poland, Greece, Germany, United Kingdom, Turkey, Czech Republic, Slovakia
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Novo Nordisk A/S

Completed

Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes (PRESENT)

Diabetes Mellitus, Type 2 | Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Slovakia
Novo Nordisk A/S

Completed

Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Norway, Sweden
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety of NovoMix® 30 FlexPen®

Diabetes Mellitus, Type 2 | Diabetes

Tunisia
Novo Nordisk A/S

Completed

Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes (REACH)

Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Canada
Novo Nordisk A/S

Completed

Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Delivery Systems

Indonesia
Novo Nordisk A/S

Completed

Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands (SWITCH)

Diabetes Mellitus, Type 2 | Diabetes

Netherlands
Novo Nordisk A/S

Completed

Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes

Jordan
Eli Lilly and Company

Completed

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

Diabetes Mellitus, Type 2

United States, Puerto Rico
Novo Nordisk A/S

Completed

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany, Poland, Russian Federation, Spain, Sweden, Netherlands, Singapore, Malaysia, France, Croatia, Romania, United Kingdom, Hong Kong
Novo Nordisk A/S

Completed

Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

Diabetes Mellitus, Type 2 | Diabetes

Hungary

3

Subscribe